Tetravil is an immunocytokine, composed of the F8 antibody that recognizes the alternatively spliced EDA domain of fibronectin coupled with the immunoregulatory cytokine interleukin 4 (IL-4). The localization and retention of IL-4 allows an increased therapeutic index of the cytokine specifically at the sites of disease.
Tetravil shows unprecedented therapeutic activity in various models of rheumatoid arthritis, psoriasis, experimental autoimmune encephalomyelitis and endometriosis.
Tetravil is the first immunocytokine in Philogen's pipeline that is showing activity in both oncology and autoimmune disease indications.
Kawalkowska et al. (2016) Eur. J. Immunol. 46:1246-57;
Quattrone et al. (2015) Reprod. Science 22:1143-1152;
Hemmerle et al. (2015) J. Dermatology 76:96-103;
Hemmerle and Neri (2014) Int. J. Cancer 134:467-77;
Hemmerle et al. (2014) EULAR, Paris;
Hemmerle et al. (2014) Proc. Natl. Acad. Sci. USA 111:12008-12.